Sergei I. Kuznetsov
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sergei I. Kuznetsov has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Evgenii I. Pugachev
Samara State Medical University
2 shared publications - Larisa Teodorovna Volova
Samara State Medical University
2 shared publications - Natalya Ossina
Samara State Medical University
2 shared publications - Oksana A. Gusyakova
Samara State Medical University
2 shared publications - Кузнецов Сергей Иванович
ФГБОУ ВО «Самарский государственный медицинский университет» Минздрава России
2 shared publications - Denis G. Alekseev
Samara State Medical University
1 shared publication
Latest Publications
- Open Access
- 6 May 2024
- Published by FSBEI of Higher Education SamSMU of Ministry of Health of the Russian Federation in Science and Innovations in Medicine
- Vol. 9 (1) , 14-21
In vitro cell-based Hyperuricemia-hemotest bioassay for cytokine status evaluation in patients with gouty arthritis
Aim– to develop anin vitromethod for assessing the activity of the inflammasome under conditions of hyperuricemic stimulation of inflammatory interleukins. Material and methods.Whole blood cells of donors and patients with hyperuricemia and exacerbation of gouty arthritis diluted with RPMI were culturedin vitroin the presence of different concentrations of uric acid. The production of cytokines in the cell growth media of hematopoietic cells stimulated with uric acid was evaluated using an enzyme-linked immunosorbent assay (ELISA). Results.By simulating the hyperuricemiain vivo, anin vitrocell-based bioassay was developed to stimulate blood cells of individual donors with uric acid. Using the developedin vitroHyperuricemia-hemotest bioassay, quantitative differences were found in the production of inflammatory cytokines by the blood cells of potentially healthy donors and patients with hyperuricemia and gouty arthritis. Conclusion.As a new approach in personalized diagnostics, a hyperuricemic (HU)-hemotest system was developed, which can serve as anin vitrocell model for studying the activation of inflammasome by inflammatory signaling molecules in gouty arthritis.
- 6 May 2024
- Published by FSBEI of Higher Education SamSMU of Ministry of Health of the Russian Federation in Science and Innovations in Medicine
- Vol. 9 (1) , 14-21
Open AccessIn vitro cell-based Hyperuricemia-hemotest bioassay for cytokine status evaluation in patients with gouty arthritis
Aim– to develop anin vitromethod for assessing the activity of the inflammasome under conditions of hyperuricemic stimulation of inflammatory interleukins. Material and methods.Whole blood cells of donors and patients with hyperuricemia and exacerbation of gouty arthritis diluted with RPMI were culturedin vitroin the presence of different concentrations of uric acid. The production of cytokines in the cell growth media of hematopoietic cells stimulated with uric acid was evaluated using an enzyme-linked immunosorbent assay (ELISA). Results.By simulating the hyperuricemiain vivo, anin vitrocell-based bioassay was developed to stimulate blood cells of individual donors with uric acid. Using the developedin vitroHyperuricemia-hemotest bioassay, quantitative differences were found in the production of inflammatory cytokines by the blood cells of potentially healthy donors and patients with hyperuricemia and gouty arthritis. Conclusion.As a new approach in personalized diagnostics, a hyperuricemic (HU)-hemotest system was developed, which can serve as anin vitrocell model for studying the activation of inflammasome by inflammatory signaling molecules in gouty arthritis.
- Open Access
- 2 December 2022
- Published by FSBEI of Higher Education SamSMU of Ministry of Health of the Russian Federation in Science and Innovations in Medicine
- Vol. 7 (4) , 250-257
Donor-specific production of cytokines by blood cells under the influence of immunomodulators: New aspects of a personalized approach in medicine
Aim – to study the immunomodulator-induced individual cytokine production by peripheral blood mononuclear cells (PBMCs) and to evaluate the potential of using this approach as a universal cellular test system in personalized medicine. Material and methods. The peripheral blood mononuclear cells given by donors were cultured in vitro in the presence of immunomodulators Imunofan and Polyoxidonium. After incubation, the enzyme-linked immunosorbent assay (ELISA) of the culture medium for the presence of pro-inflammatory cytokines IL-6, IL-8/CXCL8, MCP-1/CCL2, and IFN-α cytokines was performed. Results. The results of the experiment have demonstrated the absence of spontaneous or immunomodulator-induced production of IFN-α by PBMCs. These data correspond to the information presented earlier in the scientific literature. We also observed a pronounced inhibitory effect of both immunomodulators on the production of cytokines MCP-1/CCL2, IL-6, IL-8/CXCL8 by PBMCs, along with the individual variability of their production and the cumulative effect of production over time. Conclusion. The features of the production of pro-inflammatory cytokines by PBMCs into the medium in the presence of immunomodulators, revealed by the in vitro screening, can be used to develop universal in vitro cellular test systems for personalized diagnosis of a number of socially significant inflammatory and autoimmune diseases.
- 2 December 2022
- Published by FSBEI of Higher Education SamSMU of Ministry of Health of the Russian Federation in Science and Innovations in Medicine
- Vol. 7 (4) , 250-257
Open AccessDonor-specific production of cytokines by blood cells under the influence of immunomodulators: New aspects of a personalized approach in medicine
Aim – to study the immunomodulator-induced individual cytokine production by peripheral blood mononuclear cells (PBMCs) and to evaluate the potential of using this approach as a universal cellular test system in personalized medicine. Material and methods. The peripheral blood mononuclear cells given by donors were cultured in vitro in the presence of immunomodulators Imunofan and Polyoxidonium. After incubation, the enzyme-linked immunosorbent assay (ELISA) of the culture medium for the presence of pro-inflammatory cytokines IL-6, IL-8/CXCL8, MCP-1/CCL2, and IFN-α cytokines was performed. Results. The results of the experiment have demonstrated the absence of spontaneous or immunomodulator-induced production of IFN-α by PBMCs. These data correspond to the information presented earlier in the scientific literature. We also observed a pronounced inhibitory effect of both immunomodulators on the production of cytokines MCP-1/CCL2, IL-6, IL-8/CXCL8 by PBMCs, along with the individual variability of their production and the cumulative effect of production over time. Conclusion. The features of the production of pro-inflammatory cytokines by PBMCs into the medium in the presence of immunomodulators, revealed by the in vitro screening, can be used to develop universal in vitro cellular test systems for personalized diagnosis of a number of socially significant inflammatory and autoimmune diseases.